Actinium Pharmaceuticals Inc (ATNM) Stock Faces Higher Risks Forward After Forming Bearish Head & Shoulders Pattern

July 18, 2017 - By Clifton Ray

Investors sentiment decreased to 1 in 2016 Q4. Its down 1.14, from 2.14 in 2016Q3. It worsened, as 3 investors sold Actinium Pharmaceuticals Inc shares while 7 reduced holdings. 4 funds opened positions while 6 raised stakes. 5.73 million shares or 8.13% less from 6.24 million shares in 2016Q3 were reported.
Kcg accumulated 13,535 shares. State Street holds 0% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 11,700 shares. Susquehanna Intl Gru Limited Liability Partnership stated it has 0% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Raymond James Fincl Ser Advisors owns 17,200 shares. Northern Trust holds 0% or 62,800 shares. 15,000 are owned by Barclays Public Ltd Com. Renaissance Tech Lc holds 0% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 114,532 shares. Blackrock Institutional Tru Com Na has invested 0% in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM). Two Sigma Ltd Company stated it has 33,986 shares. Sabby Mgmt Limited Liability Company reported 0.04% stake. Hartford Fincl Management has 0% invested in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 7,000 shares. Dowling Yahnke Limited Liability Corp has 22,870 shares. Fincl Bank Of Montreal Can holds 0% or 2,500 shares. Blackrock Inv Management Limited Liability Company holds 0% or 6,869 shares in its portfolio. Royal Natl Bank Of Canada holds 4,450 shares or 0% of its portfolio.

Since June 15, 2017, it had 3 buys, and 0 sales for $18,370 activity. O’Loughlin Steve bought $4,095 worth of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) on Thursday, June 15. SETH SANDESH had bought 7,500 shares worth $8,725.

The stock of Actinium Pharmaceuticals Inc (ATNM) formed H&S with $1.02 target or 4.00 % below today’s $1.06 share price. The 8 months Head & Shoulders indicates high risk for the $62.55 million company. It was reported on Jul, 18 by If the $1.02 price target is reached, the company will be worth $2.50 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.95% or $0.01 on July 17, reaching $1.06. About shares traded. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has declined 15.34% since July 18, 2016 and is downtrending. It has underperformed by 32.04% the S&P500.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) Ratings Coverage

Among 2 analysts covering Actinum Pharma (NYSEMKT:ATNM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Actinum Pharma had 2 analyst reports since October 15, 2015 according to SRatingsIntel. FBR Capital initiated Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) rating on Thursday, October 15. FBR Capital has “Outperform” rating and $12.0 target. The firm has “Buy” rating given on Thursday, August 25 by Roth Capital.

More notable recent Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) news were published by: which released: “Actinium Pharmaceuticals Appoints Jeannine Larrieux, Ph.D. as Director of …” on December 19, 2016, also with their article: “Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent …” published on July 13, 2017, published: “Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017” on February 10, 2017. More interesting news about Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) were released by: and their article: “EMA says Actinium Pharma’s late-stage Iomab-B study sufficient for marketing …” published on March 21, 2017 as well as‘s news article titled: “Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr …” with publication date: May 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.